GB2209939B - The use of 13,14-dihydro-15-keto-prostaglandins as ocular hypotensive agents - Google Patents

The use of 13,14-dihydro-15-keto-prostaglandins as ocular hypotensive agents

Info

Publication number
GB2209939B
GB2209939B GB8821104A GB8821104A GB2209939B GB 2209939 B GB2209939 B GB 2209939B GB 8821104 A GB8821104 A GB 8821104A GB 8821104 A GB8821104 A GB 8821104A GB 2209939 B GB2209939 B GB 2209939B
Authority
GB
United Kingdom
Prior art keywords
prostaglandins
keto
dihydro
hypotensive agents
ocular hypotensive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
GB8821104A
Other languages
English (en)
Other versions
GB2209939A (en
GB8821104D0 (en
Inventor
Ryuzo Ueno
Ryuji Ueno
Tomio Oda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ueno Seiyaku Oyo Kenkyujo KK
R Tech Ueno Ltd
Original Assignee
Ueno Seiyaku Oyo Kenkyujo KK
R Tech Ueno Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26532381&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB2209939(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ueno Seiyaku Oyo Kenkyujo KK, R Tech Ueno Ltd filed Critical Ueno Seiyaku Oyo Kenkyujo KK
Publication of GB8821104D0 publication Critical patent/GB8821104D0/en
Publication of GB2209939A publication Critical patent/GB2209939A/en
Application granted granted Critical
Publication of GB2209939B publication Critical patent/GB2209939B/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GB8821104A 1987-09-18 1988-09-08 The use of 13,14-dihydro-15-keto-prostaglandins as ocular hypotensive agents Expired - Lifetime GB2209939B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP23589087 1987-09-18
JP33403787 1987-12-29

Publications (3)

Publication Number Publication Date
GB8821104D0 GB8821104D0 (en) 1988-10-05
GB2209939A GB2209939A (en) 1989-06-01
GB2209939B true GB2209939B (en) 1992-01-02

Family

ID=26532381

Family Applications (1)

Application Number Title Priority Date Filing Date
GB8821104A Expired - Lifetime GB2209939B (en) 1987-09-18 1988-09-08 The use of 13,14-dihydro-15-keto-prostaglandins as ocular hypotensive agents

Country Status (11)

Country Link
US (1) US5001153A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (2) EP0455264B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JPH02108A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR930000051B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (2) ATE82499T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1328075C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (2) DE3876050T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2052735T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB2209939B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3006319T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ226197A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1322749C (en) * 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US6420422B1 (en) 1987-09-18 2002-07-16 Sucampo Pharmaceuticals, Inc. Ocular hypotensive agents
US5236907A (en) * 1988-10-01 1993-08-17 R-Tech Ueno Ltd. Ocular hypotensive agents
JP2597629B2 (ja) 1988-02-26 1997-04-09 株式会社 上野製薬応用研究所 １３，１４−ジヒドロ−１５−ケトプロスタグランジン類の安定化
US5296504A (en) * 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5321128A (en) * 1988-09-06 1994-06-14 Kabi Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
EP1300150A3 (en) * 1988-09-06 2003-05-14 Pharmacia Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US6187813B1 (en) 1990-04-10 2001-02-13 Pharmacia & Upjohn Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
EP1224935A3 (en) 1988-09-06 2003-03-26 Pharmacia Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5194429A (en) * 1988-10-01 1993-03-16 K.K. Ueno Seiyaku Oyo Kenkyujo Ocular hypotensive agents
ATE162074T1 (de) * 1988-10-01 1998-01-15 R Tech Ueno Ltd Oculare hypotensive mittel
DE69019431T2 (de) * 1989-07-27 1995-09-14 Ueno Seiyaku Oyo Kenkyujo Kk Verwendung von 15-Keto-Prostansäure-Derivaten zur Herstellung eines Medikaments für die Verbesserung der Ausscheidung des Kaliumions.
US5234954A (en) * 1989-07-27 1993-08-10 K.K. Ueno Seiyaku Oyo Kenkyujo Treatment of hyperlipidemia with 15-keto-prostaglandin compounds
ATE121624T1 (de) * 1989-08-09 1995-05-15 Ueno Seiyaku Oyo Kenkyujo Kk Verwendung von prostansäurederivaten zur herstellung von arzneimitteln zur verbesserung der ausscheidung von nichtprotein in die därme.
CA2027814C (en) * 1989-10-20 1996-07-30 Ryuji Ueno Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
CA2030345C (en) * 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
US5256696A (en) * 1989-11-22 1993-10-26 Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo Treatment of cardiac dysfunction with 15-ketoprostaglandin compounds
US5254588A (en) * 1989-11-22 1993-10-19 Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo Treatment of pulmonary dysfunction with 15-ketoprostaglandin compounds
KR100224951B1 (ko) * 1990-03-08 1999-10-15 시오노 요시히코 15-데옥시프로스타글란딘유도체
TW249226B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1990-04-04 1995-06-11 Aderk Ueno Kk
ATE174221T1 (de) * 1990-05-01 1998-12-15 R Tech Ueno Ltd Behandlung von pankreaskrankheit mit 15-keto- prostaglandin e-derivaten
ATE91419T1 (de) * 1990-05-22 1993-07-15 R Tech Ueno Ltd Synergistische kombination zur ophthalmischen verwendung.
ES2067864T3 (es) * 1990-05-22 1995-04-01 R Tech Ueno Ltd Tratamiento de la hipertension ocular con una combinacion sinergica para administracion ocular.
CA2042934C (en) * 1990-05-22 2002-04-23 Ryuji Ueno Treatment of ocular hypertension with an ocular synergistic combination
ES2084771T3 (es) * 1990-05-22 1996-05-16 R Tech Ueno Ltd Tratamiento de la hipertension ocular con la ayuda de una combinacion sinergica.
US5175189A (en) * 1990-05-22 1992-12-29 K.K. Ueno Seiyaku Oyo Kenkyujo Treatment of ocular hypertension with a synergistic combination for ophthalmic use
CA2046069C (en) * 1990-07-10 2002-04-09 Ryuji Ueno Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
US5270049A (en) * 1990-11-09 1993-12-14 Allergan, Inc. 2-decarboxyl-2-aminoalkyl-prostaglandins as ocular hypotensives
US5139491A (en) * 1990-12-06 1992-08-18 Allergan, Inc. 2-decarboxyl-2-alkoxyalkyl prostaglandins as ocular hypotensives
TW210287B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1991-03-01 1993-08-01 Kabushikaisha Ueno Seiyaku Oyo Kenkyujo
DK0503887T3 (da) * 1991-03-14 1996-09-16 R Tech Ueno Ltd Fremme af sårheling med 15-ketoprostaglandinforbindelser
CA2065889C (en) * 1991-10-02 2002-08-27 Tetsuya Sugiyama Increasing the choroidal blood flow
EP0668076B1 (en) * 1992-08-26 2002-09-04 Sucampo AG Stabilization of a prostanoic acid compound
FR2707295A1 (fr) * 1993-06-07 1995-01-13 Rhone Poulenc Agrochimie Fongicides pyrazoles substitués en position 3 par un hétérocycle.
US6184250B1 (en) 1993-08-03 2001-02-06 Alcon Laboratories, Inc. Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US5387608A (en) * 1993-08-17 1995-02-07 Allergan, Inc. Cyclopentane(ene) heptanoic or cyclopentane(ene) heptenoic acid, 2-hydrocarbyl sulfonamidomethyl and derivatives thereof as therapeutic agents
CA2138181A1 (en) * 1993-12-15 1995-06-16 Verney L. Sallee Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
US5807892A (en) * 1994-09-30 1998-09-15 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
TW420611B (en) * 1995-03-10 2001-02-01 R Tech Ueno Ltd Pharmaceutical composition containing prostanoic acid compounds for the treatment of optic nerve disorder
WO1997023225A1 (en) * 1995-12-22 1997-07-03 Alcon Laboratories, Inc. Combinations of dp and fp type prostaglandins for lowering iop
WO1998021181A2 (en) * 1996-11-12 1998-05-22 Alcon Laboratories, Inc. 15-fluoro prostaglandins as ocular hypotensives
US6680339B2 (en) 1996-11-12 2004-01-20 Alcon Manufacturing, Ltd. 15-fluoro prostaglandins as ocular hypotensives
AU5439398A (en) 1996-11-12 1998-06-03 Alcon Laboratories, Inc. Cis-delta4 analogs of prostaglandins as ocular hypotensives
JP4397973B2 (ja) 1997-02-04 2010-01-13 ジョンストン， マーレイ エイ． 瞼の毛髪の成長を刺激するための局所的組成物
JP2001514628A (ja) 1997-03-07 2001-09-11 アルコン ラボラトリーズ，インコーポレイテッド 緑内障治療に用いるための１３−チアプロスタグランジン
US6770675B2 (en) 1997-03-17 2004-08-03 Novartis Ag Compositions and methods for reducing ocular hypertension
DK0979652T3 (da) 1997-10-13 2006-09-11 R Tech Ueno Ltd Helbredende præparat til intraokulær hypertension eller glaukom
US6156785A (en) * 1998-01-23 2000-12-05 Merck Sharp & Dohme B.V. Method for increasing oxygen tension in the optic nerve and retina
US6096783A (en) * 1998-12-15 2000-08-01 Alcon Laboratories, Inc. Cyclobutane prostaglandin analogues as ocular hypotensive agents
ATE289817T1 (de) * 1998-12-25 2005-03-15 Sucampo Ag Arzneimittelzusammenstellung zur behandlung des erhöhten augeninnendrucks oder des glaukom
SE9900672D0 (sv) 1999-02-25 1999-02-25 Synphora Ab Method and composition for prevention of scar formation in glaucoma filtration bleb and drainage fistula
JP4834224B2 (ja) 1999-03-05 2011-12-14 デューク ユニバーシティ Ｃ１６不飽和ｆｐ−選択的プロスタグランジン類縁体
TWI225398B (en) * 1999-07-14 2004-12-21 R Tech Ueno Ltd Composition for treatment of external secretion disorders
AU2603301A (en) * 1999-12-22 2001-07-03 Alcon Universal Limited 6-keto prostaglandin F1alpha and analogs for treating dry eye
US6548535B2 (en) * 2000-01-18 2003-04-15 Merck & Co., Inc. Method for treating ocular hypertension
US6545036B2 (en) 2000-01-18 2003-04-08 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
CN100506232C (zh) * 2000-03-16 2009-07-01 苏坎波公司 用于治疗眼压过高和青光眼的组合物
US6458836B1 (en) 2000-03-16 2002-10-01 Sucampo, A.G. Treatment of ocular hypertension and glaucoma
DE60138371D1 (de) * 2000-03-24 2009-05-28 Sucampo Ag PROSTAGLANDINE zur Behandlung von Lichtstrahlung erzeugten Augenerkrankungen wie Photoretinitis
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020146439A1 (en) * 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
US20020035148A1 (en) * 2000-07-20 2002-03-21 Ryuji Ueno Treatment of ocular hypertension
US6414021B1 (en) * 2000-08-25 2002-07-02 Sucampo Ag Control of intraocular pressure during surgery
ATE490761T1 (de) * 2000-09-13 2010-12-15 Santen Pharmaceutical Co Ltd Augentropfen
US6291522B1 (en) * 2000-09-27 2001-09-18 Allergan Sales, Inc. Cyclopentane heptan(ENE)oic acid, 2-thiocarbamoyloxy and 2-carbamoyloxy compounds as therapeutic agents
US20040254230A1 (en) * 2001-12-03 2004-12-16 Ogidigben Miller J. Method for treating ocular hypertension
US8758733B2 (en) 2002-02-04 2014-06-24 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US9216183B2 (en) 2002-02-04 2015-12-22 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US7351404B2 (en) 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
EP1487438A4 (en) * 2002-03-15 2007-08-15 Merck & Co Inc COMPOSITIONS AND METHODS FOR TREATING GLUCKOM AND OKULAR HYPERTENSION
AU2003233731A1 (en) * 2002-06-06 2003-12-22 Xavier Billot 1,5-disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases
EP1515721A4 (en) * 2002-06-14 2006-07-26 Merck & Co Inc OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION
CA2488884A1 (en) * 2002-06-17 2003-12-24 Merck & Co., Inc. Novel maxi-k channel blockers, methods of use and process for making the same
AU2003245565B2 (en) * 2002-06-17 2008-01-03 Banyu Pharmaceutical Co., Ltd. Ophthalmic compositions for treating ocular hypertension
US7294646B2 (en) * 2002-06-17 2007-11-13 Merck & Co. Inc. Maxi-k channel blockers, methods of use and process for making the same
US8580851B2 (en) * 2002-08-21 2013-11-12 Sucampo Ag Ophthalmic solution
EP1545517A1 (en) * 2002-08-28 2005-06-29 Merck Frosst Canada & Co. Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma
TWI337881B (en) * 2002-08-29 2011-03-01 Santen Pharmaceutical Co Ltd Treating agent for glaucoma comprising rho kinase inhibitor and prostaglandin
EP1558602A2 (en) * 2002-10-25 2005-08-03 Merck Frosst Canada Inc. 2-pyrrolidones as ep4 receptor agonists
US7972612B2 (en) 2002-11-18 2011-07-05 Santen Pharmaceutical Co., Ltd. Remedy for glaucoma comprising Rho kinase inhibitor and β-blocker
EP1610776A4 (en) * 2003-03-27 2007-03-28 Merck & Co Inc OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA
US20060199863A1 (en) * 2003-07-31 2006-09-07 Santen Pharmaceutical Co., Ltd. Product containing prostaglandin
TWI348386B (en) * 2003-08-12 2011-09-11 R Tech Ueno Ltd Composition and method for promoting hair growth
PL1681059T3 (pl) * 2003-11-07 2010-01-29 Senju Pharma Co Kompozycja farmaceutyczna zawierająca prostaglandynę
CN101072568A (zh) * 2004-12-09 2007-11-14 参天制药株式会社 含有分子内具有氟原子的前列腺素的制品
WO2006068266A1 (ja) * 2004-12-24 2006-06-29 Santen Pharmaceutical Co., Ltd. プロスタグランジンＦ２ａ誘導体含有製品
US20070298134A1 (en) * 2004-12-29 2007-12-27 R-Tech Ueno, Ltd. Composition and Method for Scalp and Hair Treatment
EP2308495A1 (en) * 2005-03-04 2011-04-13 Sucampo AG Method and composition for treating peripheral vascular diseases
JP4648340B2 (ja) * 2006-02-07 2011-03-09 株式会社アールテック・ウエノ １５−ケトプロスタグランジンｅ誘導体の製造法
WO2007105691A1 (ja) * 2006-03-13 2007-09-20 R-Tech Ueno, Ltd. 水性組成物
US20090018204A1 (en) * 2007-07-13 2009-01-15 Brinkenhoff Michael C Composition and method for enhancing hair growth
US7705001B2 (en) * 2008-03-18 2010-04-27 Allergan, Inc Therapeutic substituted gamma lactams
EP2288600A1 (en) 2008-04-24 2011-03-02 Allergan, Inc. Substituted arylcyclopentenes as prostaglandin ep2 agonists
WO2009132088A1 (en) 2008-04-24 2009-10-29 Allergan, Inc. Substituted gamma lactams as therapeutic agents
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8623918B2 (en) 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US20100204335A1 (en) * 2008-12-01 2010-08-12 Allergan, Inc. Kit and composition for eyelash growth
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
US8609729B2 (en) 2009-04-15 2013-12-17 Sucampo Ag Method for treating macular degeneration
EP3421030A1 (en) 2009-11-09 2019-01-02 Allergan, Inc. Compositions and methods for stimulating hair growth
US9149484B2 (en) 2009-11-09 2015-10-06 Allergan, Inc. Compositions and methods for stimulating hair growth
EP2600825B1 (en) 2010-08-02 2018-12-12 Ac Patent Holding Inc. Method for curling hair
US8859616B2 (en) 2011-01-21 2014-10-14 Allergan, Inc. Compounds and methods for enhancing hair growth
TW201906614A (zh) 2011-02-04 2019-02-16 日商興和股份有限公司 青光眼或高眼壓症之預防或治療用之點眼藥
KR20140035363A (ko) 2011-04-07 2014-03-21 수캄포 아게 안정피로 치료 방법
MX359697B (es) * 2011-08-05 2018-10-08 Sucampo Ag Metodo para tratar esquizofrenia.
AR092821A1 (es) 2012-04-20 2015-05-06 Sucampo Ag Conjugado de derivado de acido graso-polimero
EP3209331B1 (en) 2014-10-20 2023-07-12 Sentiss Pharma Private Limited Ophthalmic solution

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0284180A1 (en) * 1987-01-28 1988-09-28 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1476661A (en) * 1974-05-13 1977-06-16 American Cyanamid Co Prostaglandins
US4599353A (en) * 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
ES2053458T3 (es) * 1986-03-13 1994-08-01 Univ Columbia Utilizacion de prostaglandinas a, b y c y derivados de las mismas, para el tratamiento de la hipertension ocular y glaucoma.
US4824857A (en) * 1986-05-16 1989-04-25 Yasumasa Goh Use of prostaglandin D2 -active substances
CA1322749C (en) * 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
CA1324129C (en) * 1987-04-30 1993-11-09 Ryuzo Ueno Prostaglandins of the f series
ES2038289T3 (es) * 1987-05-15 1993-07-16 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Utilizacion de 15-ceto-pges para la fabricacion de un medicamento para aumentar la temperatura corporal.
JPS6453101A (en) * 1987-05-25 1989-03-01 Kurashiki Boseki Kk Equal tilt angle interference type film thickness gauge
JP2597629B2 (ja) * 1988-02-26 1997-04-09 株式会社 上野製薬応用研究所 １３，１４−ジヒドロ−１５−ケトプロスタグランジン類の安定化

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0284180A1 (en) * 1987-01-28 1988-09-28 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Arch. int. Pharmacodyn 1974,207,131-138 *

Also Published As

Publication number Publication date
NZ226197A (en) 1992-02-25
ATE82499T1 (de) 1992-12-15
EP0308135A3 (en) 1989-06-14
KR890004707A (ko) 1989-05-09
JPH02108A (ja) 1990-01-05
US5001153A (en) 1991-03-19
DE3876050D1 (de) 1992-12-24
EP0308135A2 (en) 1989-03-22
EP0455264A3 (en) 1991-11-27
AU2231388A (en) 1989-03-23
GB2209939A (en) 1989-06-01
CA1328075C (en) 1994-03-29
GB8821104D0 (en) 1988-10-05
AU600168B2 (en) 1990-08-02
ES2052735T3 (es) 1994-07-16
KR930000051B1 (ko) 1993-01-06
JPH0571567B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1993-10-07
GR3006319T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1993-06-21
DE3876050T2 (de) 1993-03-25
DE3850676D1 (de) 1994-08-18
JPH0680571A (ja) 1994-03-22
EP0455264B1 (en) 1994-07-13
EP0455264A2 (en) 1991-11-06
EP0308135B1 (en) 1992-11-19
ATE108330T1 (de) 1994-07-15
JP2592204B2 (ja) 1997-03-19
DE3850676T2 (de) 1994-11-03

Similar Documents

Publication Publication Date Title
GB2209939B (en) The use of 13,14-dihydro-15-keto-prostaglandins as ocular hypotensive agents
TW218869B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR1100989A (pt) Composto e composição de matéria
EG18729A (en) Compound of n- amino - 1,2,4-triazinones used as insecticide.
EP0563345A4 (en) Novel 4-arylpiperazines and 4-arylpiperidines
DE3785570D1 (de) Zusammensetzungen enthaltend lhrh-analoga.
ZA893346B (en) Anticoagulant peptide alcohols
EP0285167A3 (en) N-silyl substituted 1-sila-2-azacyclopentanes
UA37239C2 (uk) Хлорметилдіарилоксирани
GB8627181D0 (en) Softening detergent compositions
ATE68486T1 (de) 1-((2-fluorophenyl)(4-fluorophenyl)phenylmethyl - 1h-imidazol.
IT8420775V0 (it) Corpo musicale, nonche' di illuminazione, automatico.
ZA929176B (en) Aminoalkyl-substituted 5,6-dihydro-dibenz(b e)azepine-6,11-dione-11-oximes.
KR950009091B1 (en) Antidepressants containing 1-benzyl-aminoalkyl-pyrrolidinones
AU2196188A (en) 1(2h)-phthalazinones as cytoprotective agents
GR3005058T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT2342B (lt) 2,6-dioksopiperazino gavimo budas
IT8619209A0 (it) Procedimento per l'epossidazione di composti olefinici.

Legal Events

Date Code Title Description
732 Registration of transactions, instruments or events in the register (sect. 32/1977)
PE20 Patent expired after termination of 20 years

Expiry date: 20080907